Neoantigen vaccine + PD-1 blockade phase 1 trial was feasible and generated tumor-specific immune responses in many patients. The trial involved high-grade serous ovarian cancer.
Key points
Feasibility: treatment was feasible.
Immune response: led to tumor-specific immune responses in many patients.
Sources
Voyager 1 reaches one light-day from Earth
Voyager 1 has been breaking its own distance records for years. It is now one light-day from Earth.
Key points
Distance record: breaking its own distance records for years
Current distance: one light-day from Earth
Sources
- Original post
- Going the distance - Linked page
Johnson & Johnson–Bristol Myers Squibb alliance stroke update
Johnson & Johnson–Bristol Myers Squibb alliance update on stroke prevention, FXI(a) inhibition, and emerging anticoagulant research is now available on demand. Industry Therapeutic Updates are accessible through the AAN Online Learning Center.
Key points
Alliance update covers stroke prevention, FXI(a) inhibition, emerging anticoagulant research.
Industry Therapeutic Updates are now on demand via the AAN Online Learning Center.
Sources
- Original post
- hubs.la - Linked in the post
Updates in MSA – CSF assay distinguishes MSA with type 2 fluorescence
Updates in MSA reports a CSF seeding assay that uses thioflavin T fluorescence to differentiate MSA from controls, showing a type 2 response pattern. The assay reports high specificity and sensitivity. Prevalence estimates cite MSA at 2–5 per 100,000 and Parkinson’s disease at 130–170 per 100,000.
Key points
CSF assay produces a type 2 fluorescence response linked to MSA.
Reported prevalence: MSA 2–5/100,000, Parkinson’s disease 130–170/100,000.
Sources
- Original post
- Updates in MSA - Linked page
